Nilotinib
Composition
The formulation contains Nilotinib as the active ingredient.
Indications
Chronic myeloid leukemia
Side effects
Fatigue, headache, electrolytes abnormalaties
Precautions
Monitor for QT prolongation and electrolyte abnormalities.
Contraindications
Hypersensitivity to Nilotinib or any component, severe hepatic impairment
Dosage and administration
As directed by oncologist
Countries
Canada, UK, France
Available Forms
Oral capsule